Original content by Evgeny Ledin based on participation in international clinical trials, publications in The Lancet, NEJM, Cancers, and co-authorship of RUSSCO national guidelines.
Select a category or read all articles
A new Food & Function study: even a healthy diet does not always provide 500 mg of flavonols per day — fewer than 20% of participants reached the target level. What this means for diet and supplements in cancer care, and why supplements during treatment must be discussed with your doctor.
What is known about five Russian developments: indications, public insurance coverage, study phase, and why there is still a gap between regulatory clearance and proven efficacy. Comparison with the level of evidence from KEYNOTE-942.
The world's largest medical equipment exhibition: 5,000 brands on 320,000 m². AI embedded in MRI, CT, and surgical robots. Transbronchial robots for early lung cancer diagnosis, 7T MRI for Alzheimer's. What matters for patients — and the gap between a booth and routine clinical practice.
How China's healthcare works: NHSA, 95% insurance coverage, price negotiations (up to 63% reduction), case-group payments. Notes after training at Duke Kunshan University. What from the Chinese experience applies — and what does not.
CAR-T has become routine for blood cancers. But solid tumors are harder: difficult tumor access, lack of safe targets, immunosuppressive microenvironment. I review where early signals are emerging — gliomas, gastric cancer (CLDN18.2), hepatocellular carcinoma — and what this means for patients.
The MATTERHORN trial (NEJM, 2025) changed the standard of care for gastric cancer. 948 patients, 26 countries — adding immunotherapy to chemotherapy before and after surgery increased 2-year survival to 67% and tripled the rate of complete response. I participated in this trial as an investigator.
In 2025, I chaired the RUSSCO working group on clinical guidelines for small bowel cancer and ampulla of Vater tumors. These are rare tumors accounting for less than 6% of all GI malignancies. That is precisely why standardized treatment is so important. I explain what changed in the new edition and what it means for patients.
RUSSCO guidelines for malignant tumors of the liver and biliary system are updated annually. The 2025 edition, which I co-authored, establishes new immunotherapy-targeted therapy combinations for unresectable hepatocellular carcinoma and updates treatment algorithms for cholangiocarcinoma. I explain the key changes in plain language.
Ampulla of Vater tumors are a rare location often confused with pancreatic cancer. I presented a report on therapy selection for these patients at the XXIX Russian Oncology Congress (RUSSCO 2025, 20,000+ attendees). With early detection, the prognosis is significantly better than for pancreatic tumors.
20 years in oncology — from the Military Medical Academy through the Ministry of Health Rehabilitation Center and Medsi Group to my own clinic in Khamovniki, Moscow. 500 sq.m., Orbis scalp cooling system, an oncopsychologist, and consultation recordings — what I wanted to create for my patients.
Many patients are unaware that cancer treatment in Russia follows strict protocols developed by RUSSCO. I chair the working group on small bowel cancer guidelines (2025) and co-author liver cancer guidelines. I explain what "treatment according to protocol" really means and why it matters.
When your doctor has participated in NEJM and Lancet studies, it means they know the protocols from the inside, have seen results firsthand, and have access to the most current treatment regimens. I explain how my research experience benefits each individual patient. See treatment results.
A cancer diagnosis should not depend on geography. Online consultation with document review, second opinion on test results, medical concierge for organizing a visit to Moscow — I explain what options are available for patients from other regions and abroad.
EGFR, BRAF, PD-L1, HER2, MSI, ALK — behind these acronyms lies the principle of modern oncology: treatment is selected not by organ, but by the molecular "portrait" of the tumor. In the ADMIRE and IMbrave050 trials, biomarkers determined the choice of therapy. Learn more about services and treatment methods.
IMbrave050 (The Lancet, 2023) — the first positive adjuvant therapy trial for hepatocellular carcinoma. 668 patients from 134 centers. The combination of atezolizumab and bevacizumab reduced the risk of recurrence by 28%. I participated in this study, and now my patients receive this treatment.
The ADMIRE study (Cancers, 2021), where I am the second author: real-world data on targeted therapy for BRAF melanoma from 12 Russian centers. Combination therapy achieved a response in 57% of patients. Key finding: real-world practice differs significantly from clinical trials — more than half of patients had brain metastases.
My PhD dissertation (2008) focused on this very topic: how to protect cancer patients from hepatitis B. The result: 100% protection in vaccinated patients versus 10% infection rate in the control group. Today, infection safety is an integral part of treatment in my practice.
Articles provide general information. For an accurate assessment of your situation, a personal consultation with a review of your records is needed. Find answers to common questions on the FAQ page.
By appointment only. Mon–Fri, 10:00–16:00 (MSK).